Remove 2022 Remove Competition Remove Specialization
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. In order to bring it to market, a special program called Risk Evaluation and Mitigation Strategy (REMS) had to be put in place, where only eligible patients could access the drug through a very strict process. Competition starts to heat up. Classic treatment options. About the author.

article thumbnail

The Value of Precision Livestock Farming (PLF) in 2022

Celeritas

Monitoring and analysis of special and temporal data on cattle location, movement, and interaction can provide benefits such as. The provision of a competitive advantage over other dairy suppliers also plays a major role in the considerations. Checking their current physical condition. Determining which animals are high-performing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Major M&A deals on 2023 agenda, says report

European Pharmaceutical Review

Global M&A activity in 2022. The global life sciences mergers and acquisitions (M&A) investment totalled $105 billion in the first 11 months of 2022, with total deal value well down on 2021. EY’s research observed an overall drop in 2022 M&A investment worldwide. Biopharma alone held over $1.4

article thumbnail

Biopharma struggling to find talent with adequate digital skills

European Pharmaceutical Review

A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.

article thumbnail

Five IDNs to watch in 2023

Clarivate

In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

The consensus is 2022 was a challenging year for digital health companies. billion in 2022 — down 56% from $40.2 billion in 2022 — down 56% from $40.2 Rather, 2022 represents an overdue correction in the midst of global economic uncertainty after a period of overexuberance and lofty expectations in digital health.

Pharma 108
article thumbnail

IP management round-up: year-end reflections

Clarivate

As we say goodbye to 2022 and look forward to the year ahead, it is a great opportunity to reflect on the topics we covered in our blog series on IP lifecycle management. In case you missed any insights, here’s a round-up of the 2022 blog series. Climate innovations. Clarivate leadership recognized.